Dianthus Therapeutics (NASDAQ:DNTH) Sees Large Volume Increase on Analyst Upgrade

Key Points

• Dianthus Therapeutics' stock price increased after Guggenheim raised its price target from $92.00 to $100.00, resulting in a trading volume spike of 117%.
• Multiple research firms have upgraded their price targets on the stock, with an average price target of $60.67 and a consensus rating of "Buy."
• The company reported earnings of ($0.88) per share, missing expectations, and has a market capitalization of $1.17 billion.

Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) shares saw unusually-strong trading volume on Wednesday after Guggenheim raised their price target on the stock from $92.00 to $100.00. Guggenheim currently has a buy rating on the stock. Approximately 804,682 shares traded hands during trading, an increase of 117% from the previous session's volume of 371,567 shares.The stock last traded at $36.09 and had previously closed at $35.57.

Several other research firms have also weighed in on DNTH. Robert W. Baird boosted their price objective on shares of Dianthus Therapeutics from $50.00 to $67.00 and gave the stock an "outperform" rating in a research note on Tuesday. HC Wainwright restated a "buy" rating and set a $40.00 price objective on shares of Dianthus Therapeutics in a research note on Monday. Wedbush boosted their price objective on shares of Dianthus Therapeutics from $34.00 to $42.00 and gave the stock an "outperform" rating in a research note on Thursday, August 21st. Finally, William Blair assumed coverage on shares of Dianthus Therapeutics in a report on Wednesday, July 2nd. They set an "outperform" rating for the company. Eight research analysts have rated the stock with a Buy rating, According to MarketBeat, the company currently has a consensus rating of "Buy" and an average price target of $60.67.

Institutional Trading of Dianthus Therapeutics

Institutional investors have recently bought and sold shares of the business. Raymond James Financial Inc. bought a new stake in Dianthus Therapeutics in the 2nd quarter valued at about $27,000. US Bancorp DE increased its position in Dianthus Therapeutics by 2,013.3% during the 1st quarter. US Bancorp DE now owns 1,585 shares of the company's stock worth $29,000 after purchasing an additional 1,510 shares in the last quarter. BNP Paribas Financial Markets acquired a new position in Dianthus Therapeutics during the 4th quarter worth approximately $59,000. GAMMA Investing LLC increased its position in Dianthus Therapeutics by 3,030.6% in the 1st quarter. GAMMA Investing LLC now owns 3,882 shares of the company's stock valued at $70,000 after acquiring an additional 3,758 shares during the period. Finally, Tower Research Capital LLC TRC increased its position in Dianthus Therapeutics by 330.7% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,320 shares of the company's stock valued at $80,000 after acquiring an additional 3,317 shares during the period. Institutional investors own 47.53% of the company's stock.

Dianthus Therapeutics Trading Up 2.5%

The company's 50-day simple moving average is $21.89 and its 200-day simple moving average is $20.20. The stock has a market capitalization of $1.17 billion, a price-to-earnings ratio of -11.22 and a beta of 1.46.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.86) by ($0.02). The company had revenue of $0.19 million for the quarter, compared to the consensus estimate of $0.87 million. Dianthus Therapeutics had a negative return on equity of 34.72% and a negative net margin of 2,364.56%. On average, equities research analysts expect that Dianthus Therapeutics, Inc. will post -2.61 earnings per share for the current fiscal year.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.